How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

calendar_today November 5, 2026 person Abdullah Amin domain vima-therapeutics

BOSTON, Mass., November 5, 2026 — Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first participant has been dosed in its Phase 2 Vista PD clinical trial evaluating VIM0423 for the treatment of tremor insufficiently responsive to dopaminergic therapy in adults with Parkinson’s disease​. The company also […] The post Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy appeared first on Vima Therapeutics .

open_in_new Read original post